Nexalin Technology announces results from trial using its DIFS technology

Nexalin Technology announced results from a clinical trial demonstrating improvements in memory and cognitive function for patients with mild Alzheimer’s disease using its proprietary Deep Intracranial Frequency Stimulation, DIFS, technology. The full results have been published in Alzheimer’s Research & Therapy, one of the leading peer-reviewed journals in the field, further underscoring the scientific rigor and clinical importance of this research. Key Findings: Significant Memory Function Improvement: The DIFS group exhibited a statistically significant improvement in memory, as measured by the Alzheimer’s Disease Assessment Scale-Cognitive Subscale, compared to the sham group. Cognitive Gains: Patients treated with DIFS saw meaningful progress in global cognitive function, with significant increases in Mini-Mental State Examination scores and Montreal Cognitive Assessment scores. Increased Hippocampal Activity and Blood Flow: Functional MRI revealed enhanced neural activity and increased blood flow in the hippocampus, a critical region for memory processing, suggesting that DIFS may positively influence brain function and slow the progression of Alzheimer’s disease. Tolerability: The treatment was well-tolerated, with minor side effects such as mild tingling during stimulation sessions, all of which resolved quickly.